Thomas Helland's picture

Thomas Helland

Postdoctoral Fellow
  • E-mailThomas.Helland@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
  • Show author(s) 2021. Generating a precision endoxifen prediction algorithm to advance personalized tamoxifen treatment in patients with breast cancer. Journal of Personalized Medicine. 1-23.
  • Show author(s) 2021. Effect of genetic variability in 20 pharmacogenes on concentrations of tamoxifen and its metabolites. Journal of Personalized Medicine. 1-12.
  • Show author(s) 2021. Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ breast cancer. 1-34.
  • Show author(s) 2020. Relationship between CYP2D6 genotype, tamoxifen metabolites, and adverse events, tumor biomarkers and breast cancer recurrence in a low-dose phase III trial in noninvasive disease. Journal of Clinical Oncology.
  • Show author(s) 2020. Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen. Molecular Oncology. 11 pages.
  • Show author(s) 2020. First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: A case study. ESMO Open. 1-5.
  • Show author(s) 2019. Tamoxifen in the treatment of luminal breast cancer. Implications of active metabolites on gene expression, side effects and clinical outcome.
  • Show author(s) 2019. Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Research and Treatment. 185-195.
  • Show author(s) 2018. A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway.
  • Show author(s) 2018. A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 57-70.

More information in national current research information system (CRIStin)